Former Chief Executive Officer, Foundation Medicine
Troy Cox, former Chief Executive Officer of Foundation Medicine, is the Chairman of Sophia Genetics, Vice Chairman at LetsGetChecked, and Independent Board Director at Zymeworks and BioSplice, as well as non-profits MassBio and Dream Foundation.
Mr. Cox was the President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche valuing FMI at $5.3 billion. Prior to Foundation Medicine, he served as Senior Vice President and Officer at Genentech; leading U.S. BioOncology for a period of unprecedented growth to over $12 billion; participating in the launch of nearly half of the products from the world’s oncology leader; and steering the Roche Genentech R&D portfolio. Before Genentech, he held executive and senior roles of increasingly broad accountabilities including President of UCB BioPharmaceuticals, Senior Vice President of Sanofi-Aventis, and diverse foundational roles at Schering-Plough.
Mr. Cox received his Bachelor of Business Administration in finance from the University of Kentucky and his Master of Business Administration from the University of Missouri.